BostonGene and Saga University Announce Collaboration to Uncover Biomarkers for Improved Immunotherapy Response in Lung Cancer Patients
Still, acquired resistance often leads to recurrence within 1 to 2 years, presenting a challenge for post-treatment optimization.
- Still, acquired resistance often leads to recurrence within 1 to 2 years, presenting a challenge for post-treatment optimization.
- However, combination therapy with ICIs and anti-angiogenic agents has shown promise in EGFR-positive lung cancer.
- By partnering with BostonGene, we aim to uncover novel biomarkers to revolutionize how we approach immunotherapy treatment in EGFR-positive lung cancer, ultimately improving patient outcomes,” said Dr. Naoko Aragane, Professor of Saga University.
- “Our collaboration with Saga University underscores our dedication to advancing the standard of care in Japan by bringing novel technologies to the region.